No Photo Available

Last Update

2016-07-12T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Phillip Furman?

Dr. Phillip A. Furman

President

International Society for Antiviral Research

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

International Society for Antiviral Research

Background Information

Employment History

Southern Capitol Ventures

Vice President Biology

Pharmasset Inc

Director of Virology

Wellcome Research Laboratories

Director of Virology

Burroughs Wellcome Fund

Co-Founder and the Chief Scientific Officer

Triangle Pharmaceuticals

Senior Strategist and Virologist

The Kucera Companies

Affiliations

Member
International Society for Antiviral Research

Member
Inter-Company Collaboration

Chairman of the Admissions Committee
Biochemistry and Journal of Biological Chemistry

Member
AIDS Drug Development

Member of Scientific Advisory Board
Kucera Pharmaceutical Company

Education

B.S.

Biology and Chemistry

Piedmont College

M.A.

Microbiology

University of South Florida

Ph.D.

doctorate

microbiology

Tulane University

Web References (34 Total References)


Pharmasset, Inc. - Press Releases

investor.pharmasset.com [cached]

Atlanta, GA (February 4, 2004) - Pharmasset is pleased to announce the appointment of Phillip A. Furman, Ph.D. to the position of Vice President, Biological Sciences. Prior to joining Pharmasset, Dr. Furman was a co-founder and the Chief Scientific Officer of Triangle Pharmaceuticals, an antiviral drug discovery and development com... Read more


Management Team - Pharmasset, Inc.

www.pharmasset.com [cached]

Phillip A. Furman, Ph.D. - Vice President, Biological Sciences

Phillip A. Furman, Ph.D. is our Vice President, Biological Sciences and has been with Pharmasset since February 2004.From October 2001 to February 2004, Dr. Furman was a consultant for Bukwang Pharm.Co., Ltd. and other organizations.Prior to joining Pharmasset, Dr. Furman was a co-founder and the Chief Scientific Officer of Triangle Pharmaceuticals, an antiviral drug discovery and development company, which was acquired by Gilead Sciences.While at Triangle from 1995 to October 2001, he oversaw the activities of the virology group and reviewed antiviral and anticancer licensing candidates.During his 20-plus year tenure in drug discovery and development with Burroughs Wellcome, most recently as the Director of the Division of Virology from 1989 to 1995, Dr. Furman was a co-inventor of the use of Retrovir for the treatment of HIV and Epivir for the treatment of HBV.He has also been involved in the clinical development of numerous antiviral agents, including Zovirax (acyclovir), Retrovir, Emtriva, Ziagen, Agenerase (amprenavir) and Viroptic (trifluridine).Dr. Furman is an author of over 80 scientific publications, and he is named as an inventor on more than 20 patents.Dr. Furman received a B.S. in Biology and Chemistry from Piedmont College, an M.A. in Microbiology from the University of South Florida, and a Ph.D. in Microbiology from Tulane University.


About Southern Capitol Ventures

www.southerncapitolventures.com [cached]

Phil Furman, PhD


About Southern Capitol Ventures

www.southerncapitolventures.com [cached]

Dr. Phil Furman

Phil is Vice President of Biological Sciences at Georgia-based Pharmasset, an emerging pharmaceutical company committed to the discovery, development, and commercialization of novel antiviral drugs. He is the former chief scientific officer for Triangle Pharmaceuticals, which was acquired for $464 million by Gilead Sciences (NASDAQ:GILD). The company developed new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus. The company had an existing portfolio of five licensed drug candidates and several drug candidates. Previously, he served as director of Virology at Burroughs Wellcome, where he played a significant role in the development of AZT, acycolvir, abacavir, valtrex and agenerase and is listed as a co-inventor on over 20 patents. His research at Burroughs Wellcome focused on the structure and function of nucleic acid polymerizing enzymes. He is named co-inventor of the use of AZT for HIV therapy. He is the author of over 80 publications.
Phil continues to review articles for the following journals: Antimicrobial Agents and Chemotherapy, Biochemistry and Journal of Biological Chemistry and has been a section editor for Current Drugs. >From 1993-1995, he was a member of the scientific panel of the Inter-Company Collaboration for AIDS Drug Development and was the Chairman of the Admissions Committee for the organization. Phil received an M.A. in microbiology from the University of Southern Florida and a Ph.D. in microbiology from Tulane University and completed his post-doctoral training at Duke University.
...
Phil Furman, PhD


Southern Capitol Ventures

www.southerncapitolventures.com [cached]

Dr. Phil Furman

Phil is Vice President of Biological Sciences at Georgia-based Pharmasset, an emerging pharmaceutical company committed to the discovery, development, and commercialization of novel antiviral drugs.He is the former chief scientific officer for Triangle Pharmaceuticals, which was acquired for $464 million by Gilead Sciences (NASDAQ:GILD).The company developed new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.The company had an existing portfolio of five licensed drug candidates and several drug candidates.Previously, he served as director of Virology at Burroughs Wellcome, where he played a significant role in the development of AZT, acycolvir, abacavir, valtrex and agenerase and is listed as a co-inventor on over 20 patents.His research at Burroughs Wellcome focused on the structure and function of nucleic acid polymerizing enzymes.He is named co-inventor of the use of AZT for HIV therapy.He is the author of over 80 publications.
Phil continues to review articles for the following journals: Antimicrobial Agents and Chemotherapy, Biochemistry and Journal of Biological Chemistry and has been a section editor for Current Drugs. >From 1993-1995, he was a member of the scientific panel of the Inter-Company Collaboration for AIDS Drug Development and was the Chairman of the Admissions Committee for the organization.Phil received an M.A. in microbiology from the University of Southern Florida and a Ph.D. in microbiology from Tulane University and completed his post-doctoral training at Duke University.
...
Phil Furman, PhD

Similar Profiles

Other People with this Name

Other people with the name Furman

Danielle Furman
Pure Yoga Inc

William Furman
City of Mentor

Michael Furman
Microsoft Corporation

Clare Furman
Klein Tools Inc

Sean Furman
DePauw University

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory